Question explored with the scientific record
Clinical trials have found that prophylactic vitamin D supplementation decreases the risk of developing pneumonia in children. is this true
The short version: the evidence for prophylactic vitamin D preventing pneumonia in children is weak, inconsistent, and mostly comes from studies that did not test what you are asking.
The most recent and comprehensive evidence is a 2025 systematic review and meta-analysis of 17 randomized controlled trials covering 18,372 children [11]. It found that vitamin D supplementation did not reduce the overall incidence of acute respiratory infections (RR 0.82, p=0.13). A signal appeared only in a subgroup analysis of daily low-dose regimens (≤1000 IU/day), but subgroup findings are hypothesis-generating, not proof. The same review found no effect on hospitalization duration, recovery time, or mortality [11].
The older evidence is mixed and lower quality. A 2011 review noted that observational studies consistently link low vitamin D levels to higher pneumonia risk, but the few intervention trials showed inconsistent results [12]. One 2010 trial in Afghanistan found a single 100,000 IU dose reduced repeat pneumonia (RR 0.78) but did not affect initial recovery [12]. A 2009 trial in US adults found 2000 IU daily did nothing for upper respiratory infections [24]. The 2025 meta-analysis is the best evidence we have, and it says the intervention does not work for the general pediatric population.
The mechanism is plausible: vitamin D supports immune function, and deficiency is clearly associated with infection risk [14]. But association is not causation, and the intervention trials have not delivered. The burden of proof is on the supplement, and it has not been met.
My call: prophylactic vitamin D supplementation does not reduce pneumonia risk in children based on current evidence. Confidence: moderate, because the 2025 meta-analysis is the largest and most recent, but the evidence is still heterogeneous and the subgroup signal needs confirmation.
| Outcome | Effect (RR) | 95% CI | p-value |
|---|---|---|---|
| Overall ARI incidence | 0.82 | 0.64–1.06 | 0.13 |
| ARI with daily ≤1000 IU | 0.42 | 0.27–0.66 | <0.001 |
| Hospitalization duration | MD 0.03 days | -0.72 to 0.78 | 0.94 |
| All-cause mortality | 0.88 | 0.60–1.28 | 0.50 |
Sources used 32
-
Vitamin A supplementation and increased prevalence of childhood diarrhoea and acute respiratory infections
This study investigates the effects of vitamin A supplementation on childhood morbidity, revealing an increased prevalence of diarrhoea and respiratory infections among children receiving the supplement in Haiti.
DOI: 10.1016/0140-6736(93)91410-n -
Vitamin D exposure during pregnancy, but not early childhood, is associated with risk of childhood wheezing
This study investigates the association between vitamin D exposure during pregnancy and early childhood with the risk of childhood wheezing, finding that maternal vitamin D supplementation during pregnancy is linked to lower odds of wheezing, while early childhood vitamin D leve…
DOI: 10.1017/s2040174415001063 -
Is Vitamin B6 Supplementation of Isoniazid Therapy Useful in Childhood Tuberculosis?
This study investigates the necessity of vitamin B6 supplementation in isoniazid therapy for childhood tuberculosis, concluding that such supplementation is unnecessary as no neurological disorders were observed in the treated children.
DOI: 10.1177/004947559802800218 -
Prenatal Vitamin D Supplementation and Child Respiratory Health: A Randomised Controlled Trial
This randomized controlled trial investigated the effects of prenatal vitamin D supplementation on childhood respiratory health, finding no significant difference in wheezing or allergic diseases among children at age three, despite improved vitamin D levels in supplemented moth…
DOI: 10.1371/journal.pone.0066627 -
Micronutrients in childhood nutrition
Iron, vitamin A, and zinc deficiencies are major drivers of poor growth and immune function in early childhood, and interventions such as intermittent iron supplementation, vitamin A and zinc supplementation, and home fortification can reduce anemia, diarrhoeal morbidity, and mo…
DOI: 10.4038/sljch.v41i4.4976 -
Prenatal exposure to medication and risk of childhood cancer – a systematic review and meta-analysis
A comprehensive systematic review and meta-analysis assessing whether maternal medication use during pregnancy influences the risk of childhood cancer in offspring, finding increased risk with prenatal antibiotics (notably ALL and medulloblastoma) and nitrosatable antibiotics, r…
DOI: 10.1186/s12885-025-15316-0 -
Maternal and child's vitamin D supplement use and vitamin D level in relation to childhood lung function: the KOALA Birth Cohort Study
The KOALA Birth Cohort Study found no significant association between maternal and child vitamin D levels or supplementation and lung function in children aged 6-7 years, with some maternal supplementation linked to lower lung function scores.
DOI: 10.1136/thx.2010.151985 -
577: Vitamin c supplementation for pregnant smokers to improve lung function at birth and reduce childhood asthma: a decision analysis
This study evaluates the public health implications of vitamin C supplementation for pregnant smokers, finding that it could significantly reduce childhood asthma and mortality associated with in utero smoke exposure.
DOI: 10.1016/j.ajog.2016.11.311 -
Decline in incidence of medulloblastoma in children
This study assesses the age-standardized incidence of medulloblastoma in the West Midlands, finding a non-significant decline in cases from 1976 to 1991, contrasting with previous reports from the Southwest of England.
DOI: 10.1002/1097-0142(19950701)76:1<155::aid-cncr2820760127>3.0.co;2-q -
Effects of Maternal Vitamin D Supplementation on Childhood Health
This is a comprehensive systematic review assessing whether maternal vitamin D supplementation during pregnancy (≥400 IU/day) influences a range of offspring health outcomes across growth, bone, enamel, immune function, neurodevelopment, and respiratory health, finding mixed org…
DOI: 10.1210/endrev/bnaf034 -
The role of vitamin D in the prevention and treatment of acute respiratory infections in pediatric populations: a systematic review and meta-analysis of randomized controlled trials
A comprehensive PRISMA-guided systematic review and meta-analysis of 17 randomized controlled trials (18,372 pediatric participants) found that vitamin D supplementation does not reduce overall ARI incidence or most clinical outcomes in children, though daily low-dose regimens (…
DOI: 10.1186/s12887-025-06361-6 -
Vitamin D and Acute Respiratory Tract Infection
A comprehensive review summarizing evidence that low vitamin D status is associated with higher risk of acute respiratory tract infections (ARTI) in both developing and developed countries, and that vitamin D supplementation can reduce ARTI risk in certain populations, though re…
DOI: 10.2174/157339811798072586 -
Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults
Prospective cohort study in healthy adults linking monthly 25-hydroxyvitamin D levels to incidence of acute viral respiratory tract infections, identifying a threshold of 38 ng/mL above which infection risk and illness burden were substantially reduced, suggesting vitamin D opti…
DOI: 10.1371/journal.pone.0011088 -
COMPARISON OF SERUM LEVELS OF VITAMIN A, VITAMIN D AND ZINC IN ACUTE LOWER RESPIRATORY TRACT INFECTIONS IN CHILDREN
A matched case-control study of 82 children in eastern India found significantly lower mean serum vitamin A, vitamin D, and zinc concentrations in 51 children with acute lower respiratory infections than in 31 controls (all p<0.001), and vitamin D status was significantly associ…
DOI: 10.36106/ijsr/6400473 -
Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: “Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths” Nutrients 2020, 12(4), 988
The authors argue that recommending 10,000 IU/d of vitamin D3 to reduce COVID-19 risk is inappropriate given insufficient clinical evidence and potential harms such as reduced bone mineral density. They advise against high-dose supplementation until results from ongoing trials a…
DOI: 10.3390/nu12061626 -
Association Between Vitamin D Levels and Long COVID Signs and Symptoms
A cross-sectional Thai study of 170 adults with mild COVID-19 found that vitamin D deficiency is strongly associated with higher prevalence and number of long COVID signs across eight body systems, suggesting that maintaining adequate vitamin D may reduce long-term COVID manifes…
DOI: 10.3390/medsci13030199 -
Cost-utility of vitamin D supplementation to prevent acute respiratory infections in children
This study conducts a Colombian, CHEERS-guided cost-utility analysis of vitamin D supplementation to prevent acute respiratory infections in children, using a decision-tree model over six months with local cost data and external ARI risk reductions, finding vitamin D to be cost-…
DOI: 10.1186/s12962-023-00433-z -
Major Approaches to the Dosage of Vitamin D in the Elderly: A Systematic Review
A systematic review of vitamin D dosing in the elderly finds that maintaining serum 25(OH)D above 30 ng/mL with 1,000-2,000 IU daily reduces falls, fractures, and may improve COVID-19 outcomes.
DOI: 10.34256/mdnt2131 -
Efficacy and Safety of Vitamin D Supplementation on Psoriasis: A Pediatric Perspective
In pediatric plaque psoriasis, daily oral Vitamin D3 supplementation (1000 IU) added to standard topical therapy significantly raises serum 25(OH)D and reduces PASI scores without causing hypercalcemia or major adverse events.
DOI: 10.21276/amit.2025.v12.i3.237 -
A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD
Vitamin D deficiency correction with two direct-observed doses of cholecalciferol (300,000 IU) over 16 weeks improves endothelial function (FMD) and reduces arterial stiffness (PWV) in non-diabetic CKD patients with stage 3–4 disease.
DOI: 10.1681/ASN.2017010003 -
Prevalence of Vitamin D Deficiency and Effects of Supplementation With Cholecalciferol in Patients With Chronic Kidney Disease
A 6-month prospective open-label interventional study in nondialysis chronic kidney disease patients showed that roughly half were vitamin D deficient, and daily cholecalciferol (1000 IU) effectively restored 25(OH)D levels in the majority, with iPTH decreasing and calcium risin…
DOI: 10.1053/j.jrn.2013.07.003 -
Treatment with Vitamin D3 in Vitamin D Deficient Adolescents: A Pilot Study
Daily vitamin D3 (2000 IU) for 3 months increased serum 25-hydroxyvitamin D by 56% and normalized levels (≥20 ng/mL) in about 80% of vitamin D–deficient, otherwise healthy adolescents in Huntington Beach, CA, with no adverse effects.
DOI: 10.1177/2333794x20976240 -
A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency
This randomized double-blind trial in 150 vitamin D-deficient adults found a linear dose-response relationship between vitamin D3 supplementation and 25(OH)D increases, with a 200,000 IU loading dose plus 100,000 IU monthly producing the greatest rise (+20.12 ng/mL at week 12) a…
DOI: 10.3390/nu7075227 -
A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections
A double-blind randomized trial in adults during winter found that high-dose vitamin D3 (2000 IU daily) did not reduce incidence, duration, or severity of symptomatic upper respiratory tract infections over 12 weeks, despite raising serum 25-OHD levels.
DOI: 10.1017/s0950268809002404 -
Comment On: Clinical Trial: Vitamin D3 Treatment in Crohn's Disease: A Randomized Double‐Blind Placebo‐Controlled Study
Oral vitamin D3 supplementation with 1200 IU daily increases serum 25(OH)D and is associated with a non-significant reduction in relapse risk over 12 months in Crohn's disease patients in remission compared with placebo.
DOI: 10.1177/0884533611400232 -
Analysis of serious adverse events in a pediatric community-acquired pneumonia randomized clinical trial in Malawi
Double-blind randomized non-inferiority trial in Malawi shows 3 days of amoxicillin for non-severe chest-indrawing pneumonia in HIV-uninfected children is non-inferior to 5 days with no increase in serious adverse events; SAEs were rare, with higher risk in male and younger chil…
DOI: 10.1038/s41598-022-07582-w -
Antibiotics for community-acquired pneumonia in children
This systematic review evaluates the effectiveness of various antibiotic treatments for community-acquired pneumonia in children, highlighting that amoxycillin is a viable alternative to co-trimoxazole, while also indicating the need for more studies on newer antibiotics.
DOI: 10.1002/14651858.CD004874.pub4 -
Urokinase Versus VATS for Treatment of Empyema: A Randomized Multicenter Clinical Trial
This multicenter randomized clinical trial compares the effectiveness of urokinase instillation versus video-assisted thoracoscopic surgery (VATS) for treating children with septated empyema, finding both treatments to be equally effective in reducing hospitalization time.
DOI: 10.1542/peds.2013-3935 -
Dexamethasone treatment for acute bacterial meningitis: how strong is the evidence for routine use?
A methodological appraisal of randomized trials on dexamethasone as an adjunct to antimicrobials for acute bacterial meningitis, showing none of the studies met all validity principles and concluding that routine use is not supported by robust internal validity or generalisabili…
DOI: 10.1136/jnnp.59.1.31 -
Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial
This study demonstrates that dexamethasone significantly reduces the time to recovery in children with parapneumonic pleural effusion compared to placebo, without increasing serious adverse events.
DOI: 10.1016/j.jpeds.2017.02.043 -
Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality
Pediatric PCV vaccination programs create herd protection that reduces pneumococcal disease in seniors, while PPV23 shows variable protection in older adults and overall vaccination uptake remains suboptimal, highlighting the need for targeted nursing-home strategies and surveil…
DOI: 10.3390/geriatrics6010013 -
Anifrolumab (Saphnelo)
Anifrolumab shows signal of benefit on disease activity in adults with active autoantibody-positive SLE, notably improving BICLA response in TULIP-2 and sustaining steroid-sparing signals in long-term data, but overall trial results are inconsistent and cost-effectiveness remain…
DOI: 10.51731/cjht.2023.568